Latest disclosed round
Series C/D (letter unconfirmed)
- Date
- 2023-01-01
- Amount
- USD 32m
- Sector
- Biotech & techbio
- Companies House
- 06425006
Later stage / growth
Crescendo Biologics
Antibody therapeutics (Humabody platform)
CandidateSeries CCambridge
Evidence status
Review retained
- Identity
- Candidate
- Match
- High candidate
- Operating status
- active
- Data origins
- Core directory, Growth Network, Live Chris T D1
Capital network
7 linked investors
Funding record
1 disclosed round
| Date | Stage | Amount | Investors |
|---|---|---|---|
| 2023-01-01 | Series C | $32M (tranche; total raised to date $274M) | not specified in source, Sofinnova Partners, Andera Partners, IP Group, BioNTech, Takeda, Quan Capital, Kreos Capital |
Traceability
Source trail
Funding and investor claims retain their public-source links. This is a research snapshot, not a live cap table.